Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
24,032 total articles
Eledon Pharmaceuticals reported its Q2 2026 financial results highlighting successful regulatory interactions and strong clinical data for tegoprubart in kidney and islet cell transplantation. The company is on track to start a global Phase 3 kidney transplant trial in late 2026 with promising long-term Phase 2 results showing improved kidney funct…
nCino, Inc., a US-based platform specializing in agentic AI banking for financial institutions, announced it will release its second quarter fiscal year 2027 financial results on August 25, 2026, after market close, followed by a conference call to discuss the results.
MDB Capital Holdings announced its Q2 2026 operational and financial update, showcasing successful underwriting of IPOs including Buda Juice, Ticketplus, and eXoZymes. The company expanded its pipeline of disruptive technology ventures, progressed strategic partnerships to enhance distribution, and initiated the spin-out of its AI-driven PatentVest…
MacroGenics announced solid second quarter 2026 financial results highlighted by $32.8 million in revenue driven by milestone payments, net income of $19.5 million including discontinued operations, and a strengthened cash position of $327 million after the sale of its manufacturing operations. The company is transitioning to an outsourced manufact…
CapsoVision, a medical technology company specializing in AI-enabled capsule endoscopy, reported Q2 2026 revenue of $3.6 million, up 10% year-over-year. The company launched its AI Highlights™ product in the EU and expects FDA clearance and U.S. launch by Q3 end. Product adoption across hospitals and GI networks is expanding, and the CapsoCam Colon…
Quantum-Si Incorporated announced its Q2 2026 financial results, highlighting a delay in the commercial launch of its Proteus protein sequencing platform to Q2 2027 for additional development and manufacturing readiness. The company recorded $344 thousand in revenue during the Proteus transition period, implemented a 20% workforce reduction to alig…
Roadzen Inc. announced its best quarter ever with Q1 FY2027 revenue of $16.2 million, up 49% year-over-year, driven by strong adoption of its AI platform in insurance and mobility sectors. The company improved adjusted EBITDA loss by 73% and signed a definitive agreement to acquire a European MGA specializing in short-term car rental insurance, exp…
4D Molecular Therapeutics reported strong second quarter 2026 results including completion of enrollment for its 4FRONT-2 Phase 3 trial for wet AMD, and expects topline data from both 4FRONT-1 and 4FRONT-2 trials in 2027. The company also presented positive 2-year Phase 2b data for 4D-150 and plans to initiate a Phase 3 trial for diabetic macular e…
Equillium, Inc. reported second quarter 2026 financial results highlighting progress toward clinical development of EQ504, a selective AhR modulator for autoimmune and inflammatory disorders. The company expects to initiate a Phase 1 proof-of-mechanism study in Q4 2026, with topline data anticipated about six months later. Equillium maintains a str…
PEDEVCO Corp. reported a substantial increase in revenue and net income for Q2 2026, driven by a 348% increase in production and higher oil prices following the October 2025 merger that expanded its asset base. Adjusted EBITDA rose 516% to $18.7 million, reflecting improved operational scale and financial performance. The company initiated an enhan…
Eton Pharmaceuticals reported strong Q2 2026 results with record product sales of $37.6 million, reflecting 99% growth year-over-year. The company achieved positive GAAP and non-GAAP earnings per share, expanded its rare disease portfolio with the licensing of the late-stage product ASN-001, and raised full-year revenue guidance to exceed $145 mill…
Dynagas LNG Partners LP announced a quarterly cash distribution of $0.050 per common unit for the quarter ended June 30, 2026, payable on August 28, 2026. The Partnership owns six LNG carriers operating on multi-year charters with a combined carrying capacity of approximately 914,000 cubic meters.
Jefferson Capital, Inc., a purchaser and manager of consumer receivables, announced its second quarter 2026 results highlighting an 18% increase in collections to $300.9 million and a 21% rise in deployments to $152.2 million. Estimated Remaining Collections grew 18% to $3.4 billion. The company reported pre-tax income of $53.3 million and net inco…
Capricor Therapeutics reported Q2 2026 financial results along with updates on the regulatory review of Deramiocel, their lead cell therapy for Duchenne muscular dystrophy (DMD). The FDA advisory committee voted 9-3 against substantial evidence of effectiveness of Deramiocel for treating cardiomyopathy in DMD, impacting approval prospects. However,…
Xcel Brands, Inc. reported its Q2 2026 financial results featuring a net loss of $2.5 million on a GAAP basis, an improvement compared to $4.0 million loss in the prior year quarter. Adjusted EBITDA showed a 40% improvement when excluding non-recurring expenses, driven by new influencer-led product launches and reduced operating expenses. Revenue d…
AVAX One Technology Ltd. (NASDAQ: AVX) announced its Q2 2026 financial results showing a substantial increase in total revenue to $2.8 million from $0.5 million a year earlier, primarily driven by $2.1 million in staking rewards from its Avalanche digital asset treasury and $0.7 million from bitcoin mining. Despite revenue growth, the company repor…
Vivani Medical reported Q2 2026 financial results, including a net loss of $6.4 million, while highlighting significant business progress. The company completed dosing in its SLIM-1 Phase 1 trial of NPM-139, a novel semaglutide implant for chronic weight management, with top-line data expected in November 2026. Vivani entered a non-exclusive agreem…
Rani Therapeutics reported positive Phase 1a clinical data for RT-114, an oral biologic delivery candidate demonstrating bioavailability exceeding subcutaneous dosing. The company expanded its obesity pipeline through a new collaboration with PegBio, completed a $20 million stock offering, and strengthened its leadership team. Financial results sho…
Arcadia Biosciences released its Q2 and first half 2026 financial results showing a modest decrease in revenues due to inventory and shipping delays but improved operating cash usage. The company raised $4 million via private placement and is poised for growth with new Zola product launches planned for late 2026 and early 2027. Despite operational …
Mangoceuticals' merger partner, Nuclea Energy, signed a definitive agreement to acquire Moltex Energy's advanced nuclear technology assets, including patents and technologies related to advanced reactors and nuclear fuel recycling. This acquisition is expected to broaden Nuclea's nuclear technology portfolio and provide strategic entry into multipl…
dLocal delivered robust financial results for Q2 2026, reporting a 92% year-over-year increase in total payment volume (TPV) to nearly $18 billion and record gross profit of $127 million, up 29%. Operating profit rose 15% year-over-year to $64 million, with net income increasing 28% to $55 million. The company raised its TPV and gross profit guidan…
WidePoint Corporation reported its second quarter 2026 financial results highlighting continued profitability with positive adjusted EBITDA for the 36th consecutive quarter and positive net income for the second consecutive quarter. The company was named the single awardee of the U.S. Department of Homeland Security (DHS) Cellular Wireless Managed …
Rank One Computing Corporation (ROC), a U.S.-based Vision AI leader, reported second-quarter 2026 financial results showing sequential revenue growth of nearly 100% to $5.1 million, driven by increased government R&D contracts and commercial traction across its Vision AI product portfolio. Government R&D revenues grew by 41% year-over-year, and ROC…
Invivyd, Inc. reported second quarter 2026 financial results featuring $14.3 million in net product revenue from PEMGARDA, a 21% increase year-over-year, driven by increased patient demand. The company completed enrollment in key Phase 3 clinical trials for its novel monoclonal antibody candidate VYD2311 targeting COVID-19, with top-line data antic…
Mineralys Therapeutics announced inducement equity awards granted to its newly appointed Chief Medical Officer, Dr. Terry Ferguson, including stock options and restricted stock units totaling over 237,000 shares, vesting over four years. The awards were granted under the company's 2025 Employment Inducement Incentive Award Plan in accordance with N…
